First Connecticut Bancorp, Inc. Increases Quarterly Dividend
Nov 28, 2017 21:01 pm UTC| Business
FARMINGTON, Conn., Nov. 28, 2017 -- First Connecticut Bancorp, Inc. (NASDAQ:FBNK) today announced that its Board of Directors has voted to increase its quarterly dividend to $0.15 per share, an increase of $0.01. In...
Nuance Announces Fourth Quarter and Fiscal Year 2017 Results
Nov 28, 2017 21:01 pm UTC| Business
BURLINGTON, Mass., Nov. 28, 2017 -- Nuance Communications, Inc. (NASDAQ:NUAN) today announced financial results for its fiscal 2017 and fourth quarter, ended September 30, 2017. Nuance delivered a strong fourth quarter...
Iovance Biotherapeutics to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
Nov 28, 2017 21:01 pm UTC| Business
SAN CARLOS, Calif., Nov. 28, 2017 -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced...
Independent Bank Group, Inc. to Acquire Integrity Bancshares, Inc.
Nov 28, 2017 21:00 pm UTC| Business
MCKINNEY, Texas, Nov. 28, 2017 -- Independent Bank Group, Inc. (NASDAQ:IBTX), the holding company for Independent Bank, today announced that Independent Bank Group has entered into a definitive agreement to acquire...
Independent Bank Group, Inc. Commencement of Common Stock Offering
Nov 28, 2017 21:00 pm UTC| Business
McKINNEY, Texas, Nov. 28, 2017 -- Independent Bank Group, Inc. (NASDAQ:IBTX), the holding company for Independent Bank, today announced that it has commenced an underwritten public offering of 2,135,506 shares of its...
Nuance Appoints Tom Beaudoin, Executive Vice President, Business Transformation
Nov 28, 2017 21:00 pm UTC| Business
BURLINGTON, Mass., Nov. 28, 2017 -- Nuance Communications, Inc. (NASDAQ:NUAN) today announced that it has appointed Tom Beaudoin as its executive vice president, Business Transformation. In this role, Mr. Beaudoin will...
Nov 28, 2017 21:00 pm UTC| Business
-- Results from the Phase 1 Clinical Trial of Adolescents with Angelman and Fragile X Syndromes Demonstrated OV101 was Well Tolerated with a Pharmacokinetic Profile Similar to Adults -- -- With Core Expertise in...